TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company
Transcenta, biologics, antibody
TST008 is a first-in-class tri-functional antibody combining a MASP2 antibody fused with a transmembrane activator and CAML interactor (TACI) protein, which simultaneously targets both innate and adaptive immune pathways for a potentially better efficacy for the treatment of SLE.
